

INSTITUTE FOR ANIMAL HEALTH

Director: Professor Martin W. Shirley, PhD

PIRBRIGHT LABORATORY

Ash Road,

Pirbright,

Surrey,

GU24 ONF

Intn Tel: 00 44 1483 232441

Tel: 01483 232441 Fax: 01483 232621

FMD Vaccine Matching Strain Differentiation Report

Lab Reference WRL Batch Number:

Sender Details:

Date Received:

Country of Origin:

Date Reported:

WRLFMD/2009/00034

22nd June 2009

Iran

13th November 2009



To help us improve the quality of our service, please send any suggestions or requests to the Reference Laboratory by fax (+44 (0) 1483 232621 or email: elizabeth.wilson@bbsrc.ac.uk)

Report no:	VNT								LPBE					
Vaccine: Field Isolate:		A22 Irq	A Tur06	A Sau 41/91	A Ind 17/82	A Irn87	A Irn99	A M ay 97		A22 lrq 24/64	A Eri 98	A Irn 99	A May 97	A Irn 87
A Irn 39/2009	Mean	0.34	0.52	0.21	0.10	0.09	0.08	0.09	Mean	0.50	DNT	DNT	DNT	0.19
A Irn 44/2009	Mean	0.35	>0.72	0.30	0.11	0.07	0.09	0.09	Mean	0.25	DNT	DNT	DNT_	0.09

Interpretation of Results

In the case of Virus Neutralisation Test (VNT):

 $r_1 = \ge 0.3$. Suggests that there is a close relationship between field isolate and vaccine strain. A potent vaccine containing the vaccine strain is likely to confer protection.

 $r_1 = < 0.3$. Suggests that the field isolate is so different from the vaccine strain that the vaccine is unlikely to protect

In the case of Liquid Phase Blocking Elisa (LPBE):

 $r_1 = 0.4-1.0$. Suggests that there is a close relationship between field isolate and vaccine strain. A potent vaccine containing the vaccine strain is likely to confer protection.

 r_1 = 0.2-0.39, Suggests that the field isolate is antigenically related to the vaccine strain. The vaccine strain might be suitable for use if no closer match can be found provided that a potent vaccine is used and animals are preferably immunised more than once.

 $r_1 = <0.2$. Suggests that the field isolate is so different from the vaccine strain that the vaccine is unlikely to protect.